Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 October, 2018 18:46 IST
Tata Steel's Bhushan buy to raise net leverage, offset gains from Europe JV: Fitch
Source: IRIS | 24 May, 2018, 04.25PM
Comments  |  Post Comment

Tata Steel  (TSL, BB/Rating Watch Evolving) acquisition of a controlling stake in Bhushan Steel is likely to raise TSL's leverage over the next two to three years, which will offset the benefits to its credit profile from the resultant increase in market share in India as well as reduced exposure to structural weaknesses in Europe, says Fitch Ratings.

Fitch awaits confirmation of and further information on the 50:50 JV with thyssenkrupp AG (BB+/Rating Watch Positive) in Europe, following binding agreements between the two partners, to resolve the Rating Watch on TSL's ratings.

TSL has now cleared all the regulatory hurdles needed to proceed with the acquisition after India's National Company Law Tribunal (NCLT) approved TSL's debt resolution plan for Bhushan on 15 May 2018 and the anti-trust regulator gave the greenlight in April. Bhushan, which has steelmaking capacity of around 5 million tonnes per annum (mtpa), was one of five key distressed steel assets put up for bidding under insolvency proceedings in India. Under the resolution plan, Bhushan's financial creditors will receive Rs 352 billion for settlement of existing financial debt. This amount will be financed with new secured debt of Rs 165 billion and cash on TSL's balance sheet. TSL will subsequently acquire a 72.65% equity stake in Bhushan.

TSL's projected steelmaking capacity will increase to 23mtpa with the Bhushan acquisition and including TSL's own 5mtpa capacity expansion scheduled to be completed in 2022. This is in line with management's intention of doubling capacity in India from 13mtpa in the next five years. Bhushan's main plant is relatively close, about 150km away from TSL's Kalinganagar plant in Odisha in eastern India. Bhushan's plant is underutilised, producing around 3.5mtpa currently. TSL believes its turnaround plan will enable the plant to reach close to 100% utilisation in two years.

Bhushan's plant, unlike TSL's, does not benefit from use of captive raw materials currently. However, TSL envisages gains from improvement in operating metrics and from unified marketing and procurement. Bhushan's product mix is enhanced by downstream facilities like its cold-rolling mill and galvanizing units. TSL also has the option to increase capacity at Bhushan's site in the future, which is useful given the significant time required to set up a green field plant in India.

The Bhushan acquisition will enable TSL to improve its domestic market share, but Fitch estimates it will raise TSL's leverage, in terms of net debt to EBITDA, to 4x over the next two to three years from around 3x at end-March 2018. TSL's net debt will increase by around Rs 350 billion due to the acquisition, excluding additional working capital debt at Bhushan. We assume additional EBITDA of around Rs 45 billion in the second year following the acquisition, based on an output of 5 million tonnes and an EBITDA per tonne of around Rs 9,000, based on TSL successfully improving operations at Bhushan to near-optimum levels within two years.

TSL has also shown interest in acquiring a controlling stake in another steel asset - Bhushan Power and Steel. The result of that bidding process is likely to be known within the next few months. A successful bid is likely to further increase TSL's leverage over the medium term.

Shares of the company gained Rs 9.15, or 1.7%, to settle at Rs 548.40. The total volume of shares traded was 759,045 at the BSE (Thursday).





Bhushan Steel Limited   (Q,N,C,F)*

Tata Steel Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Biocon, Mylan announce positive CHMP Opinion for Ogivri - 22-Oct-2018 10:28
Lupin announces positive CHMP opinion for NaMuscla - 22-Oct-2018 09:51
Tejas Networks bags Rs 1.11 bn order from Sterlite Technologies - 22-Oct-2018 09:45
Alembic Pharma' JV completes USFDA inspection of Karakhadi unit - 22-Oct-2018 09:41
Lupin's Pithampur unit-3 inspected by USFDA - 19-Oct-2018 16:01
Surya Roshni bags order worth Rs 503.4 mn - 19-Oct-2018 11:22
Glenmark Pharma to present data on investigational treatment for Atopic Dermatitis - 19-Oct-2018 09:55
Zydus Cadila receives tentative approval for Colchicine tablets - 18-Oct-2018 16:21
Ramco Systems partners with Airbus Helicopters SAS - 18-Oct-2018 10:26
ABB secures order worth Rs 1.15 bn from Indian Railways - 18-Oct-2018 10:20
Zydus Cadila gets nod for Clobetasol propionate cream - 17-Oct-2018 15:19
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer